drugset
drugset / Trial / NCT03283449

Tau PET Imaging in Atypical Dementias

NCT03283449 ↗

Phase 1 Completed 70 enrolled University of Chicago National Institute on Aging (NIA) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

The goal of this study is to demonstrate the feasibility of mapping tau pathology in subjects with Primary Progressive Aphasia, using PET protocol with F-AV-1451 (trade name AV-1451) and to systematically document the extent and location of tau pathology in PPA patients in vivo using the same techniques.

Timeline

Start
2016-02
Primary completion
2025-02-28
Completion
2025-02-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Flortaucipir F18 Diagnostic / imaging agent 370 mbq —

Indications

primary progressive aphasia